EQT INFRASTRUCTURE VI, THROUGH OTELLO BIDCO AB, HAS OBTAINED ALL NECESSARY REGULATORY APPROVALS AND ANNOUNCES ADDITIONAL ACQUISITIONS SECURING 70.12 PERCENT OF THE SHARES IN OX2 AB (PUBL)
This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in
Finnish biotech company NADMED has developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fresh blood in hours, with the highest accuracy on the market. NADMED provides crucial information on vitamin B3 deficiencies, which have been linked to degenerative age-related diseases such as metabolic diseases, cancer, neurodegenerative and heart diseases.HELSINKI, Finland (August 22nd, 2024) Finnish biotech company NADMED has closed a €3.5M series A round to fund its entry into the U.S. and other international
